An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.

The results from the PROMISE I feasibility study give LimFlow confidence that the PROMISE II pivotal trial will prove that the LimFlow percutaneous deep vein arterialization system is a safe and effective alternative to amputation for patients with critical limb ischemia.

Summarizing the month in European dealmaking.

Ancile Pharmaceuticals believes the time is right to profit from botanicals. The FDA has recently shown a willingness to work with companies attempting to develop herbal drugs, while consumer demand for herbal dietary supplements is mushrooming. From botanicals, Ancile plans to develop patentable, proprietary ingredients that have multiple uses, and sell products based on those ingredients in the medical foods, dietary supplement and drug markets.